関連する実験動画
Updated: Jan 9, 2026
01:27
Pulmonary Embolism III: Nursing Management
Published on: June 19, 2025
320
p62(dok):慢性骨髄性白血病の原始細胞における構成的にチロシン・フォスホル化,GAP関連タンパク質である
N Carpino1, D Wisniewski, A Strife
1Cold Spring Harbor Laboratory, Cold Spring Harbor, New York 11724, USA.
Cell
|January 24, 1997
まとめ
慢性骨髄性白血病 (CML) は,異常なp210 ((bcr-abl) タンパク質を伴う. 研究者は,GAPと関連し,CMLと受容体チロシンキナーゼ経路に関与する新しいシグナル伝達分子,p62 (((dok) を特定しました.
科学分野:
- 分子生物学は分子生物学である.
- 腫瘍学 腫瘍学
- 細胞シグナル伝達 細胞信号伝達
背景:
- 慢性骨髄性白血病 (CML) は,BCR-ABL融合タンパク質によって特徴付けられ,チロシンキナーゼ活性が上昇しています.
- CML患者の血液形成細胞は,p120 ras GTPase活性化タンパク質 (GAP) と関連した構成的にチロシン酸化62 kDaのタンパク質を示しています.
研究 の 目的:
- BCR-ABLを発現する細胞に含まれる新しい62 kDaのタンパク質を精製し,特徴づけること.
- 細胞シグナル伝達経路におけるこの新種のタンパク質の役割,特にBCR-ABLと受容体チロシンキナーゼに関連して調査する.
主な方法:
- p210 ((bcr-abl)) を発現する血液形成細胞系からp62タンパク質を浄化する.
- p120 ras GTPase活性化タンパク質 (GAP) とのタンパク質関連性の分析.
- c-Kit受容体活性化時のチロシンリン酸化状態の調査.
主要な成果:
- 新しいタンパク質をp62 (((dok) と指定し,浄化し,シグナル伝達分子として特定しました.
- p62(dok) はGAPと関連しており,この関連はチロシンリン酸化と相関しています.
- p62(dok) は,c-Kit受容体の活性化後に急速なチロシンリン酸化を受けます.
結論:
- p62 (((dok)) は,CMLの病原性に関与している新しいシグナル伝達分子です.
- p62(dok) は,c-Kit.など,受容体チロシンキナーゼのダウンストリームで機能する.
- この発見は,p62 (((dok) が白血病やその他の細胞プロセスに関連する信号伝達経路の重要な構成要素であることを示唆しています.
関連する概念動画
Pulmonary Embolism III: Nursing Management
320
A pulmonary embolism occurs when a thrombus, amniotic fluid, tumor tissue, fat, or air embolus blocks one or more pulmonary arteries. Effective nursing management and patient education are crucial for improving outcomes and preventing recurrence.Nursing management starts with obtaining a comprehensive patient history, particularly noting any history of deep vein thrombosis (DVT). Assess for clinical manifestations, including dyspnea, chest pain, crackles, heart murmurs, and signs of right-sided...
320
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
277
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
277
Pulmonary Embolism I: Introduction
464
Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
464
Venous Thrombosis III: Interprofessional Care
262
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
262
Pneumothorax-II
852
Pneumothorax is a medical condition defined by the buildup of air in the pleural space between the lungs and the chest wall. This accumulation of air can lead to partial or complete lung collapse, resulting in a range of clinical manifestations. Understanding the clinical presentation and effective management strategies is crucial for healthcare professionals in providing timely and appropriate care to individuals with pneumothorax.
Clinical Manifestations:
Clinical Manifestations:
852
Chronic Obstructive Pulmonary Disease-V: Management
3.1K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
3.1K